Axsome Therapeutics (NASDAQ:AXSM) completes patient randomization in a Phase 3 clinical trial, STRIDE-1, evaluating AXS-05 in patients with treatment-resistant depression.
The primary endpoint is the change from baseline at week 6 in the total score of a scale called MADRS. Topline results should be available later this quarter.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.